When a new drug is approved, it’s difficult to know what kind of impact it will have on your members. This is why EnvisionRx continuously monitors the drug pipeline and, as treatment options change, we evaluate and share our perspective on the clinical benefits, cost-effectiveness and overall impact to payers and patients. Join us, along with PBMI on June 26th at 1:30 p.m. ET as our clinical experts present the webinar “Perspective on the Rx Pipeline: Understanding Market Impacts and How to Improve Plan Performance.”
During the webinar, Christa Bigham, Pharm.D., RPh, MSCS, Drug Information Pharmacist for EnvisionRxOptions, Christine Anderson, Director, Clinical Services and Outcomes for EnvisionPharmacies and Ian Parnigoni, Pharm.D., RPh, Clinical Account Executive for EnvisionRx will discuss our Perspective on the Rx Pipeline (POP) reports, which provide ongoing insights with recommendations to protect and improve plan performance.
The need to continuously monitor the drug pipeline and provide this type of insight is increasingly important as treatment options change with new drugs coming to market, particularly specialty medications. In 2017, the Food and Drug Administration (FDA) approved 46 novel drugs, and this does not even include approvals for new or expanded formulations. When a drug is approved, payers must determine if it is safe, clinically sound and economically effective, as well as determine how to incorporate it in their formulary approach. Sometimes, a new-to-market drug is promoted as being revolutionary, but is simply the over-priced combination of two or more less expensive medications. An analysis of the drug pipeline, along with proposed management strategies and recommendations, can help address these issues. In fact, this evaluation and communication of clinical benefits and cost-effectiveness of newly approved medications has become critical for payers to understand this dynamic marketplace.
The webinar will provide five key ways to distill the breadth and depth of drug pipeline information to its simplest form to uncover meaningful insights for your organization. The presentation will:
- Discuss current and future trends of the drug pipeline
- Identify activities that impact drug utilization and costs
- Explain how to tailor solutions for various stakeholders
- Provide key elements of a quality pipeline product
- Assess the potential value of pipeline services
Register today to learn how to improve your plans performance!
 Advancing Health Through Innovation 2017 New Drug Therapy Approvals. U.S. Food & Drug Administration Center for Drug Evaluation and Research. https://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ReportsBudgets/UCM591976.pdf